ACE2 activation promotes antithrombotic activity
- PMID: 20111697
- PMCID: PMC2811560
- DOI: 10.2119/molmed.2009.00160
ACE2 activation promotes antithrombotic activity
Abstract
The aim of the present study was to test the hypothesis that the activation of the angiotensin-converting enzyme (ACE)2/angiotensin-(1-7)/Mas receptor axis by use of a novel ACE2 activator (XNT) would protect against thrombosis. Thrombi were induced in the vena cava of spontaneously hypertensive rats (SHR) and Wistar Kyoto (WKY) rats, and ACE2 and ACE activity in the thrombus was determined. Real-time thrombus formation was viewed through intravital microscopy of vessels in nude mice. Thrombus weight was 40% greater in the SHR (4.99 +/- 0.39 versus 7.04 +/- 0.66 mg). This weight increase was associated with a 20% decrease in ACE2 activity in the thrombus. In contrast, there were no differences between the WKY and SHR in ACE2 protein and ACE activity in the thrombi. ACE2 inhibition (DX600; 0.1 micromol/L/kg) increased thrombus weight by 30% and XNT treatment (10 mg/kg) resulted in a 30% attenuation of thrombus formation in the SHR. Moreover, XNT reduced platelet attachment to injured vessels, reduced thrombus size, and prolonged the time for complete vessel occlusion in mice. Thus, a decrease in thrombus ACE2 activity is associated with increased thrombus formation in SHR. Furthermore, ACE2 activation attenuates thrombus formation and reduces platelet attachment to vessels. These results suggest that ACE2 could be a novel target for the treatment of thrombogenic diseases.
Figures




Similar articles
-
Angiotensin-converting enzyme 2 activation protects against hypertension-induced cardiac fibrosis involving extracellular signal-regulated kinases.Exp Physiol. 2011 Mar;96(3):287-94. doi: 10.1113/expphysiol.2010.055277. Epub 2010 Dec 10. Exp Physiol. 2011. PMID: 21148624 Free PMC article.
-
Angiotensin II regulation of angiotensin-converting enzymes in spontaneously hypertensive rat primary astrocyte cultures.J Neurochem. 2016 Jul;138(1):74-85. doi: 10.1111/jnc.13641. Epub 2016 Jun 2. J Neurochem. 2016. PMID: 27085714
-
Oral administration of an angiotensin-converting enzyme 2 activator ameliorates diabetes-induced cardiac dysfunction.Regul Pept. 2012 Aug 20;177(1-3):107-15. doi: 10.1016/j.regpep.2012.05.093. Epub 2012 May 14. Regul Pept. 2012. PMID: 22595130 Free PMC article.
-
Insufficient hypothalamic angiotensin-converting enzyme 2 is associated with hypertension in SHR rats.Oncotarget. 2017 Mar 21;8(12):20244-20251. doi: 10.18632/oncotarget.15666. Oncotarget. 2017. PMID: 28423630 Free PMC article.
-
ACE2 gene transfer attenuates hypertension-linked pathophysiological changes in the SHR.Physiol Genomics. 2006 Oct 3;27(1):12-9. doi: 10.1152/physiolgenomics.00312.2005. Epub 2006 Jun 20. Physiol Genomics. 2006. PMID: 16788004
Cited by
-
Anti-infection mechanism of phosphodiesterase-5 inhibitors and their roles in coronavirus disease 2019 (Review).Exp Ther Med. 2021 Apr;21(4):320. doi: 10.3892/etm.2021.9751. Epub 2021 Feb 3. Exp Ther Med. 2021. PMID: 33732293 Free PMC article. Review.
-
Cardiovascular Complications Associated with COVID-19 and Potential Therapeutic~Strategies.Int J Mol Sci. 2020 Sep 16;21(18):6790. doi: 10.3390/ijms21186790. Int J Mol Sci. 2020. PMID: 32947927 Free PMC article. Review.
-
ACE2, Much More Than Just a Receptor for SARS-COV-2.Front Cell Infect Microbiol. 2020 Jun 5;10:317. doi: 10.3389/fcimb.2020.00317. eCollection 2020. Front Cell Infect Microbiol. 2020. PMID: 32582574 Free PMC article.
-
Covid-19 and in situ pulmonary artery thrombosis.Respir Med. 2021 Jan;176:106176. doi: 10.1016/j.rmed.2020.106176. Epub 2020 Oct 2. Respir Med. 2021. PMID: 33092932 Free PMC article. No abstract available.
-
Counter-regulatory renin-angiotensin system in hypertension: Review and update in the era of COVID-19 pandemic.Biochem Pharmacol. 2023 Feb;208:115370. doi: 10.1016/j.bcp.2022.115370. Epub 2022 Dec 5. Biochem Pharmacol. 2023. PMID: 36481346 Free PMC article. Review.
References
-
- Willoughby S, Holmes A, Loscalzo J. Platelets and cardiovascular disease. Eur J Cardiovasc Nurs. 2002;1:273–88. - PubMed
-
- Lip GY. Hypertension, platelets, and the endothelium: the “thrombotic paradox” of hypertension (or “Birmingham paradox”) revisited. Hypertension. 2003;41:199–200. - PubMed
-
- Dzau VJ. Theodore Cooper Lecture: Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension. 2001;37:1047–52. - PubMed
-
- Donoghue M, et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1–9. Circ. Res. 2000;87:E1–9. - PubMed
-
- Ferreira AJ, Raizada MK. Genomic and proteomic approaches for targeting of angiotensin-converting enzyme 2 for cardiovascular diseases. Curr Opin Cardiol. 2008;23:364–9. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous